Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003).
Fiche publication
Date publication
décembre 2020
Journal
Brain and behavior
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MEYER Nicolas, Pr DE SEZE Jérôme
Tous les auteurs :
Collongues N, Kuhle J, Tsagkas C, Lamy J, Meyer N, Barro C, Parmar K, Amann M, Wuerfel J, Kappos L, Moreau T, de Seze J
Lien Pubmed
Résumé
High-dose pharmaceutical-grade biotin (MD1003) has positive effects on disability in progressive multiple sclerosis (PMS), but its mechanism of action remains unclear. The objective of our study was to quantify the effect of MD1003 in patients with PMS, using clinical response, plasma neurofilament light chain (pNfL) levels, and brain (BV) or cervical spinal cord volume (CSCV).
Mots clés
MD1003, brain volume, multiple sclerosis, neurofilament light chain, progressive form, spinal cord volume
Référence
Brain Behav. 2020 Dec 13;:e01998